Kiniksa Pharmaceuticals, Ltd. - (KNSA): Price and Financial Metrics


Kiniksa Pharmaceuticals, Ltd. - (KNSA)

Today's Latest Price: $15.82 USD

0.61 (4.01%)

Updated Sep 25 4:00pm

Add KNSA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

KNSA Daily Price Range
KNSA 52-Week Price Range

KNSA Stock Price Chart Technical Analysis Charts


KNSA Price/Volume Stats

Current price $15.82 52-week high $28.67
Prev. close $15.21 52-week low $5.01
Day low $15.17 Volume 354,496
Day high $15.93 Avg. volume 314,072
50-day MA $18.07 Dividend yield N/A
200-day MA $18.06 Market Cap 1.07B

Kiniksa Pharmaceuticals, Ltd. - (KNSA) Company Bio


Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda


KNSA Latest News Stream


Event/Time News Detail
Loading, please wait...

KNSA Latest Social Stream


Loading social stream, please wait...

View Full KNSA Social Stream

Latest KNSA News From Around the Web

Below are the latest news stories about Kiniksa Pharmaceuticals Ltd that investors may wish to consider to help them evaluate KNSA as an investment opportunity.

Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th

- Virtual event to take place from 8:00 a.m. to 9:30 a.m. EDT - HAMILTON, Bermuda, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to modulate immunological pathways that are implicated across a spectrum of diseases, today announced that the company’s virtual Rilonacept Analyst Day will now take place on Tuesday, September 29th, 2020 from 8:00 a.m. to 9:30 a.m. Eastern Daylight Time.The event will feature presentations from the Kiniksa management team on the market opportunity for rilonacept in recurrent pericarditis as well as the company’s continued commercial preparations and launch strategy. Additionally, guest speaker Paul Cremer, MD, Cardiovascular Medicine, ...

Yahoo | September 24, 2020

Kiniksa Announces Upcoming Rilonacept Analyst Day

\- Virtual event scheduled for Monday, September 28th, 2020 from 8:00 a.m. to 9:30 a.m. EDT-HAMILTON, Bermuda, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to modulate immunological pathways that are implicated across a spectrum of diseases, today announced that the company will host a virtual Rilonacept Analyst Day on Monday, September 28th, 2020 from 8:00 a.m. to 9:30 a.m. Eastern Daylight Time. The event will feature presentations from the Kiniksa management team on the market opportunity for rilonacept in recurrent pericarditis as well as the company’s continued commercial preparations and launch strategy. Additionally, guest speaker Paul Cremer, MD, Car...

Yahoo | September 21, 2020

Kiniksa Pharmaceuticals (KNSA) Investor Presentation - Slideshow

The following slide deck was published by Kiniksa Pharmaceuticals, Ltd. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 17, 2020

Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis

Management to present at the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16th at 2pm EDTHAMILTON, Bermuda, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to mavrilimumab for the treatment of giant cell arteritis (GCA). Mavrilimumab is a monoclonal antibody inhibitor targeting granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα).“We are pleased to announce that the FDA granted Orphan Drug designation to mavrilimumab for the tre...

Yahoo | September 15, 2020

Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

HAMILTON, Bermuda , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16th, 2020 at 2:00 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.About Kiniksa Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s clinical-stage product candidates, rilonacept, mavri...

Yahoo | September 9, 2020

Read More 'KNSA' Stories Here

KNSA Price Returns

1-mo -2.89%
3-mo -31.31%
6-mo 29.46%
1-year 81.42%
3-year N/A
5-year N/A
YTD 43.04%
2019 -60.63%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6516 seconds.